Lonza announces the launch of ResistAid™, an all-natural immune health ingredient for food and dietary supplements. Boasting a potent combination of Larch Arabinogalactan and bioactive flavonoids, ResistAid™ may help in supporting immune function.
"Launching ResistAid™ is another indicator of Lonza’s continued success in the global nutritional ingredient market and we are proud to develop a beneficial immune product for food and dietary supplements," said Michael DeGennaro, Global Head of Sales and Marketing, Lonza Nutrition. "Lonza is dedicated to supplying the nutrition landscape with cutting-edge ingredients that assist the development, formulation and functionality of a myriad of nutrition products."
"Lonza’s ResistAid™ allows customers to take advantage of an all-natural product that helps support multiple components of the immune system," said Bryan Rodriguez, Technical Marketing and Scientific Affairs Manager for Lonza. "At the same time, customers can be assured that ResistAid™ is self-affirmed GRAS with U.S. Food and Drug Administration (FDA) notification and is approved by the U.S. FDA as a direct food additive. It is allergen free, with no reported side effects and has no adaptation period required. It has no known interactions with other substances and no overdose level." Manufacturers can benefit from its technical qualities as it is easily incorporated into dietary supplements, functional foods or in combination with other products to increase functionality.
Benefiting from a patented, water-based extraction process from U.S. Larch trees, ResistAid™ is manufactured according to HACCP. It is GMP-audited by the American Institute of Baking, is Kosher certified by United Mehadrin and is GMO free. ResistAid™ has a monograph in the Food Chemicals Codex FCC.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets. Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.